Fanari Zaher, Gunasekaran Prasad C, Shaukat Arslan, Hammami Sumaya, Dawn Buddhadeb, Wiley Mark, Tadros Peter
Heartland Cardiology/Wesley Medical Center, University of Kansas, Wichita, KS, United States.
Division of Cardiovascular Diseases, University of Kansas, Kansas City, KS, United States.
Cardiovasc Revasc Med. 2018 Jun;19(4):438-443. doi: 10.1016/j.carrev.2017.10.001. Epub 2017 Oct 5.
The ACC/AHA guidelines recommend low-dose dobutamine challenge for hemodynamic assessment of the severity of AS in patients with low flow, low gradient aortic stenosis with reduced ejection fraction (EF) (LFLG-AS; stage D2). Inherent pitfalls of echocardiography could result in inaccurate aortic valve areas (AVA), which have downstream prognostic implications. Data on the safety and efficacy of coronary pressure wire and fluid-filled catheter use for low dose dobutamine infusion is sparse.
We retrospectively analyzed 39 consecutive patients with EF<50%, AVA<1cm and SVI<35ml/m on echocardiography who underwent simultaneous right and left heart catheterization. Hemodynamic assessments were performed at baseline and at every increment in the dobutamine infusion rate (The infusion was continued until maximal dose of dobutamine or a mean AV gradient>40mmHg was attained. The occurrence of sustained ventricular arrhythmias, symptomatic hypotension or intolerable symptoms leading to cessation of infusion was recorded. Transient ischemic attacks (TIAs) or clinically apparent strokes periprocedurally or up to 30days after the procedure were recorded.
Dobutamine challenge confirmed true AS in 26 patients (67%) and pseudosevere AS in 34%. No sustained arrhythmias, hypotension or cessation of infusion from intolerable symptoms were observed. No clinical strokes or TIAs were observed up to 30days after procedure in any of these patients.
Hemodynamic assessment of AS using a pressure wire with dobutamine challenge is a safe and effective tool in identifying truly severe AS in patients with LFLG-AS with reduced EF.
美国心脏病学会/美国心脏协会(ACC/AHA)指南推荐,对于射血分数(EF)降低的低流量、低跨瓣压差主动脉瓣狭窄(LFLG-AS;D2期)患者,采用小剂量多巴酚丁胺激发试验进行血流动力学评估以判断主动脉瓣狭窄的严重程度。超声心动图存在的固有缺陷可能导致主动脉瓣面积(AVA)测量不准确,进而对下游的预后产生影响。关于使用冠状动脉压力导丝和充液导管进行小剂量多巴酚丁胺输注的安全性和有效性的数据较少。
我们回顾性分析了39例超声心动图显示EF<50%、AVA<1cm且每平方米体表面积的心输出量(SVI)<35ml的患者,这些患者同时接受了右心和左心导管检查。在基线时以及多巴酚丁胺输注速率每次增加时进行血流动力学评估(持续输注直至达到多巴酚丁胺最大剂量或平均主动脉瓣跨瓣压差>40mmHg。记录持续性室性心律失常、症状性低血压或导致输注停止的无法耐受症状的发生情况。记录围手术期或术后30天内的短暂性脑缺血发作(TIA)或临床明显的卒中情况。
多巴酚丁胺激发试验证实26例患者(67%)为真性主动脉瓣狭窄,34%为假性重度主动脉瓣狭窄。未观察到持续性心律失常、低血压或因无法耐受症状而停止输注的情况。在这些患者中,术后30天内均未观察到临床卒中或TIA。
对于EF降低的LFLG-AS患者,使用压力导丝联合多巴酚丁胺激发试验进行主动脉瓣狭窄的血流动力学评估是识别真正重度主动脉瓣狭窄的一种安全有效的工具。